Day 1 - Tuesday 14th February

Time Topic
07:30 - 08:25 Coffee and Registration
08:25 - 08:30 Opening address
08:30 - 09:00 Chairman Address & Presentation - Chuck Stevens, Vice President, Parexel
Session 1: Pricing & Reimbursement
09:00 - 09:35
A brave new world: The trends, challenges and strategies for effectively commercializing novel oncology products
With: Chris Boerner, Vice President of Marketing, Seattle Genetics
  • An overview of the major trends affecting oncology product commercialization.
  • How to get approval in the era of personalized medicine.
  • Developing an effective pricing & access strategy to maximise launch uptake
09:35 - 10:10
From evidence-based to value-based medicines: What does this mean for your development strategy?
With: Darshan Wariabharaj, Director, Drug Regulatory Affairs, Novartis Oncology
  • Understand developing value-based medicines - it's not just about efficacy
  • Endpoints: know what is achievable and appropriate. Are we moving beyond Overall Survival or/and Progression Free Survival?
  • Get to grips with the role of comparative effectiveness in establishing therapy value
  • Learn how to integrate your value proposition into your development strategy to improve market access
10:10 - 10:45
From evidence-based to value-based medicines: What does this mean for your commercialization strategy?
With: Quanwu Zhang, Global Evidence & Value Development, Sanofi R & D
  • Gain insight into payer, physician and patient's perspectives on endpoints
  • Understand how to improve your engagement with stakeholders and increase understanding of their endpoint requirements
  • Incorporate these perspectives into your commercialization strategy in order maximise product uptake
10:45 - 11:15 Networking coffee break
11:15 - 11:50
Evolution of Medicare and its Impact on Oncology Product Coverage and Reimbursement
With: Debbie Warner, Vice President Oncology Market Access, Kantar Health
  • Attitudes are changing on Capitol Hill towards expensive Oncology therapies.
  • Gain insight into how Medicare's reimbursement policy will evolve
  • Patient access to therapy is multi-dimensional. Understand the impact of coverage, provider reimbursement, patient affordability and delivery system availability
  • Understand how to adapt your marketing strategy to tougher market conditions and learn how to work towards sustaining current levels of access
11:50 - 12:25
A Health Plan PBM perspective on managing specialty care: Learn how your therapy will be viewed covered and reimbursed
With: Raechele McMahan, Head, Clinical Strategy & Development, Aetna Pharmacy
  • Understand how Aetna are collaborating with specialty pharmacy to manage therapy costs
  • Get insight into payer strategies in supporting community oncologists and align your reimbursement strategy
  • How Aetna develop accountable care strategies with hospitals: learn how your product will be evaluated and covered
12:25 - 13:25 Lunch
13:25 - 14:00
The importance of patient reported outcomes for your market access strategy
With: Nathan White, Executive Director, Access & Reimbursement, InVentiv Health
Steven Bloom, Vice President, ZioPharm
  • Explore key pre-launch market access considerations including vendor partnering and specialty pharmacy strategy and contracting
  • Get insight into the importance of Patient Reported Outcomes in post-launch market access efforts
  • Hear a case study from ZIOPHARM Oncology on best practices to integrate PRO into early stage market access efforts
14:00 - 14:35
Panel: How Payers are working with Oncology pathways: Learn how to align your reimbursement strategy
With: Michael Sherman, CMO, Harvard Pilgrim
Dr Beckie Fenrick, Senior Director, BlueCross BlueShield's
Raechele McMahan, Head, Clinical Strategy & Development,, Aetna Pharmacy
  • Understand both industry and regulatory perspectives as to what factors determine the value of Oncology therapies
  • Get insight into managing the balance between cost and quality of life
  • Learn from a Health plan's perspective to understand how to align your reimbursement strategy for mutual benefit
14:35 - 15:10 Networking coffee break
15:10 - 15:45
The Patient's Voice in Market Access
With: Tim Turnham, Executive Director, Melanoma Research Foundation
  • Patient advocacy groups can play a significant role in market access
  • Most companies do not establish good relations with patient groups
  • Ensure that your company is leveraging the power of patient voices
Session 2: Targeted Therapies & Companion Diagnostics
15:45 - 16:20
Panel: Deduce the new role of companion diagnostic tests in getting access for your targeted therapy
With: Marc Watrous, Vice President Payer Account Management, Genentech
Dana Evans, Medical Director, Genentech
Raechele McMahan, Head, Clinical Strategy & Development, Aetna Pharmacy
  • Having a companion diagnostic test could become a key tool in getting approval for your oncology product and for getting your drug reimbursed
  • Examine how this emerging technology will affect Payer strategies in managing increased care costs
16:20 - 16:55
Ensuring effective market access for the diagnostic associated your targeted therapy
With: Charles Mathews, Vice President, Boston Healthcare
  • Understand differences between global market access pathways for diagnostics versus drugs
  • Insights into different potential business models for CDx globally (pharma supports, payer pays, etc.)
  • Learn how to align timing and manage support activity associated with CDx
16:55 - 17:30
Super Panel discussion: Build your commercial structure for targeted therapies to gain market access
Led by Michael Sherman, CMO, Harvard Pilgrim
With... Aetna, Sanofi Oncology, BlueCross BlueShield's, Bayer and Novartis
  • Understand how to integrate your commercial needs with market access into your development programme, given the trend towards value based medicine
  • How your brand strategy evolves in light of the shift in the use of diagnostics with your targeted therapy
  • Learn how to cope with the challenges of marketing to a selected population
17:30 Networking Drinks Reception in Exhibition Area
Get the full picture - download the brochure
Download Now

Day 2 - Wednesday 15th February

Time Topic
08:20 - 08:50 Coffee and Registration
08:50 - 09:00 Chairman's opening - Nathan White, Executive Director, Access & Reimbursement, InVentiv Health
09:00 - 09:45
Diagnostic: Pricing Strategy Manage diagnostic approval processes
With: Laura Housman, Executive Director, Market Access and Pricing, Novartis Molecular Diagnostics
William Pignato, Global Head, Regulatory Affairs, Novartis Molecular Diagnostics
  • Understand pricing strategy for companion diagnostic test kits and how this will be impacted by your targeted therapy pricing strategy
  • Get to grips with the evolving business model for Companion Diagnostics developers. Know how the trend towards perceived value pricing will affect access to your product
  • Understand 510k and PMA - and what each approval route means for you and your product
  • How to manage diagnostic approval timescales to fit with your therapy approval process
09:45 - 10:20
Case Study: How to assess threat from mature products and generics when launching a new therapy
With: Suraj Moorthy, Director of Strategy & Portfolio Management, Sanofi Oncology
  • Understand how to differentiate your product from existing competition when launching a new therapy
  • Learn how to gauge your potential success from understanding what your therapy offers in terms of efficacy improvement
10:20 - 10:55
Health Plans and Oncologists: The Bumpy Road to Patient Access
With: Dawn Holcombe, President DGH Consulting
Dawn Holcombe, President DGH Consulting
  • Understand the scope and impact of market solutions for better client communication and internal strategic planning
  • Get insight into the direct and indirect concerns of plan medical directors & physicians, and develop a more mature market strategy
  • How to maximise client relationships to enhance your product value proposition
10:55 - 11:35 Networking coffee break
11:35 - 12:10
Targeted therapies: Ensure Access for Selected populations
With: Jason Carlin, Deputy Director Marketing Science, Bayer Healthcare
Andrea Adams, Associate Director Customer Analytics, Bristol-Myers Squibb
  • Understand how to adapt your marketing approach when you target small populations
  • Learn how you will need to adjust your requirements in terms of clinical liaisons and sales force
  • How to differentiate your Oncology brands which target selected populations from competing brands
12:10 - 12:45
Pre and post launch strategy: understand how to maximise product uptake:
With: Dr Andree Bates, President, Eularis
  • Learn how to maximising your launch indication
  • Get to grips with available post-launch strategies to increase product uptake
12:45 - 13:45 Lunch
Session 3: Manage & Engage your stakeholders
13:45 - 14:20
Panel: Create value-winning strategies by effective patient group engagement throughout the value chain of R&D, marketing, and market access:
Led by: Siobhan Cavanaugh, Principal, Siobhan Cavanaugh Consulting
Eric Stanek,VP Research, Medco Research Institute
Tim Turnham, Executive Director, Melanoma Research Foundation
Durhane Wong-Reiger, Chair, International Alliance of Patient Organizations
  • Learn to engage with patient groups earlier in the development process. Understand how patient groups can aid in clinical trial value-communication & recruitment (Bristol-Myers Squibb Case Study)
  • Know the global trends in patient engagement in shaping health policy: learn how to work with patient groups in supporting health technology assessment and driving access to innovative therapies
  • How innovative analytics can close the care gap between science and medical practice to improve patient health outcomes and manage costs
14:20 - 14:55
Understand the benefits of working with a new stakeholder: Specialty Pharmacy
With: Rebecca Shanahan, Board Member, Oncology Plus
Josh Rademacher, Vice President, Oncology Plus
  • Understand how innovative distribution channels can reduce exposure to high therapy costs while maintaining support to the community oncologist
  • Learn how specialty pharmacy can improve your patient assistance programmes in providing high tech infusibles
  • Hear how specialty pharmacy can work with you in reducing the cost of delivering care, maximising your product uptake and relations with payers & patients
14:55 - 15:40
Panel: The new Oncology Influencers: Why the Data Race, Partnerships, and transparency are Critical to Your Access Strategy
With: Darin T. Rubin, M.P.H, M.B.A., Pulse of the Patient
Anthony Davino, Vice President Manufacturer Relations, Armada Healthcare
Ed Rodgers, Executive Directors, Via Oncology
John Yetter, Director, Oncology Payer Marketing, Bristol-Myers Squibb
Mark Neville, Vice President, Sales & Marketing, Diplomat Specialty Pharmacy
Stuart Genschaw, Executive Director, Cancer & Hematology Centers of Western Michigan
  • How payers, providers, state societies, specialty pharmacies, GPOs, foundations, molecular diagnostics groups, & pathways programs create regional access ecosystems
  • Seize influence points & partnership opportunities to enhance the value of your oncology brands
  • Proactively engage key stakeholders to improve quality of care & access success
15:40 - 15:50 Chairman - Closing remarks - Nathan White, Executive Director, Access & Reimbursement, InVentiv Health
15:50 End of Conference!
Get the full picture - download the brochure
Download Now

Global Sponsors

Gold Sponsors

Gold Exhibitor